Objectives: Therapeutic options available to treat MRSA pneumonia are limited. Trimethoprim/sulfamethoxazole is an attractive treatment because of its bactericidal anti-MRSA activity, oral and parenteral formulations and good penetration to the lung tissue. We aimed to compare the efficacy and safety of trimethoprim/sulfamethoxazole with vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia.
Introduction
Pneumonia remains an important cause of morbidity and mortality among hospitalized patients and those in long-term-care facilities. 1 Staphylococcus aureus is a common cause of healthcare-associated pneumonia, recent epidemiological investigations indicating that the prevalence of healthcare-associated MRSA infections is rising. 2 Patients with MRSA pneumonia have significantly worse overall outcomes, including prolonged length of stay, lower rates of clinical response and a higher mortality. 3 The therapeutic options available for treating serious infections due to MRSA pneumonia are limited. According to the 2011 IDSA guidelines the management of healthcare-associated MRSA pneumonia includes the use of intravenous vancomycin or intravenous/ oral linezolid or clindamycin. The guidelines (2011) also state that additional studies are needed to determine the role of trimethoprim/sulfamethoxazole in treating MRSA pneumonia. 4, 5 Alternatives to vancomycin continue to be sought since high failure rates have been observed in the treatment of MRSA pneumonia. This has been attributed to the poor penetration of vancomycin into pulmonary tissue and lung epithelial lining fluid. 6 Trimethoprim/sulfamethoxazole has long been recognized as an antibiotic active against S. aureus. While trimethoprim is the V C The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
main active component and is of itself bactericidal, the combination is highly synergistic. 7 A recent randomized controlled trial (RCT) conducted in four acute-care hospitals in Israel compared trimethoprim/sulfamethoxazole with vancomycin for the treatment of inpatients with severe MRSA infections. The trial included 252 patients and demonstrated that trimethoprim/sulfamethoxazole was noninferior compared with vancomycin in the treatment of severe MRSA infections, particularly for patients with bacteraemia. This study included a few patients in each arm with pneumonia (10 in the trimethoprim/sulfamethoxazole arm versus 12 in the vancomycin arm), while most patients had skin and soft-tissue or bone/ joint infections. 8 Another recently published non-inferiority RCT comparing trimethoprim/sulfamethoxazole with rifampicin versus linezolid for the treatment of MRSA infections concluded that both the trimethoprim/sulfamethoxazole and rifampicin combination therapy and linezolid monotherapy were equally effective for treating patients with MRSA infection. However, only eight versus nine patients in each arm had MRSA pneumonia, with most patients once again suffering from skin and soft-tissue infections. 9 The only other antibiotic agent that has undergone in-depth clinical evaluation for the treatment of MRSA pneumonia and which is also available in an oral formulation is linezolid. A recent, large (1184 patients) RCT involving hospitalized adult patients with hospital-acquired or healthcare-associated MRSA pneumonia demonstrated greater clinical efficacy of linezolid compared with adjusted-dose vancomycin, with similar 60 day mortality. 10 The use of linezolid, however, is limited by its cost and possible drug interactions and adverse effects associated with long-term therapy. There thus remains an as yet unmet clinical need for the evaluation of other oral anti-MRSA therapies. 9 We are not aware of any studies comparing trimethoprim/ sulfamethoxazole with other anti-MRSA agents for the treatment of pneumonia.
In light of this and the fact that the use of trimethoprim/sulfamethoxazole for MRSA pneumonia is an accepted alternative in our institution, we conducted this retrospective study comparing trimethoprim/sulfamethoxazole with vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia.
Methods

Patients and study design
This is a retrospective, case-control, single-centre study using patient charts for data collection. The study was conducted at the Rabin Medical Center, Beilinson Hospital, in Petah-Tikva, Israel, a 900 bed primary-and tertiary-care, university-affiliated hospital. The hospital has four main ICUs and small high-care areas in the six internal medicine and two surgical departments in which patients undergo mechanical ventilation. Using the microbiology laboratory records from January 2010 to December 2015, we identified all consecutive patients 18 years old with a positive culture for MRSA in the sputum, susceptible to both trimethoprim/sulfamethoxazole and vancomycin. We included only patients with healthcare-or ventilatorassociated MRSA pneumonia, as defined below, who were treated with trimethoprim/sulfamethoxazole or vancomycin for at least 3 consecutive days. The decision to administer vancomycin or trimethoprim/sulfamethoxazole in our hospital is made after consultation with an infectious disease specialist. In our institution we give priority to trimethoprim/sulfamethoxazole for treating MRSA pneumonia, and only if there is contraindication to this therapy (such as drug allergy, hyperkalaemia, anaemia or leucopenia) do we administer vancomycin. Trimethoprim/sulfamethoxazole is started intravenously at a twice-daily dose of 160 mg of trimethoprim/800 mg of sulfamethoxazole. In patients who stabilize, are extubated, start eating and drinking, are without nausea and vomiting and have no fever for 448 h, trimethoprim/sulfamethoxazole is switched to oral 1 doublestrength (DS) tab twice daily. Vancomycin dosing is started at 1 g twice daily with normal creatinine clearance and is adapted according to guidelines for interrupted renal function. We excluded patients receiving another antibiotic active against MRSA at the same time as receiving trimethoprim/ sulfamethoxazole or vancomycin (activity against MRSA was defined by susceptibility in culture). We retrieved demographic, bacteriological and clinical data, including baseline patient characteristics, signs and symptoms of infection, laboratory data and antimicrobial treatment, including type of antibiotics given, time from pneumonia diagnosis to appropriate anti-MRSA treatment, dose and duration of treatment, recent antibiotics (48 h prior to sputum culture collection) and vancomycin blood levels. Primary outcomes included all-cause mortality at 30 days and clinical failure at the end of treatment, as defined in the Supplementary data available at JAC Online. Secondary outcomes included microbiological failure, as defined in the Supplementary data, length of hospitalization, duration of stay in the ICU, duration of mechanical ventilation and adverse events. The study was approved by the institutional review board, who waived the need for informed consent due to the retrospective study design.
Definitions
(i) MRSA-associated pneumonia was defined as a new or worsening infiltrate on chest X-ray combined with positive sputum culture for MRSA and at least two of the following:
9,10 fever 438 C/536.1 C; white blood cells (WBCs) 410 000/m 3 or 54000/m 3 ; purulent sputum or increase in the requirement for suctioning; new onset or worsening of cough; findings of pneumonia on auscultation; and dyspnoea or tachypnoea (respiratory rate 424/min) or hypoxia (PaO 2 /FiO 2 5240). Sputum culture was acceptable if performed within 5 days of the diagnosis. Chest X-ray was acceptable if performed within 24 h of the clinical symptoms.
(ii) Ventilator-associated pneumonia was defined as pneumonia that occurs448-72 h after endotracheal intubation.
11
(iii) Healthcare-associated pneumonia referred to any patient who: was hospitalized in an acute-care hospital for 2 days within 90 days of the infection; resided in a nursing home or long-term-care facility; received recent intravenous antibiotic therapy, chemotherapy or wound care within the past 30 days of the current infection; or attended a hospital or haemodialysis clinic. 11 
Statistical methods
Continuous variables are expressed as the mean + SD. Categorical data are summarized as frequencies and percentages. Characteristics of patients were compared between the groups, stratified by antibiotic treatment, using the t-test for continuous variables and the v 2 test or Fisher's exact test for dichotomous variables, as appropriate. All P values were two-sided and a P value of50.05 was considered significant.
In order to reduce bias affecting the decision to use a specific antibiotic and as a sensitivity analysis, a propensity-score model for choosing between vancomycin and trimethoprim/sulfamethoxazole was used to match patients. The variables for the propensity score were chosen based on univariate analysis (P50.5) or those deemed clinically significant.
Matching was performed using nearest neighbour matching with a 1:1 ratio, restricted by a calliper of 0.5 of the standard deviation of the propensity score and done without replacement.
Analyses were conducted using IBM SPSS Statistics 20 (IBM, Armonk, NY, USA) and the R language for statistical computing (Vienna, Austria).
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Results
During the study period we identified 42 patients with MRSA pneumonia treated with trimethoprim/sulfamethoxazole and 39 treated with vancomycin. The demographic and clinical characteristics of the patients in both groups are shown in Table 1 . Overall, no significant differences were demonstrated between groups in the baseline characteristics, including functional capacity, underlying conditions and baseline laboratory and clinical variables upon infection onset. The only significant difference was a higher rate of urinary catheterization at diagnosis (42.9% versus 66.7%) and lower albumin level (mean values 2.93 versus 2.55 g/dL) in the vancomycin group versus the trimethoprim/sulfamethoxazole group, respectively (P50.05 for both). While the trimethoprim/ sulfamethoxazole group had a trend to more ICU-acquired infections (31% versus 15.4%, P " 0.09), no significant difference between the two groups was found in the incidence of ventilatorassociated pneumonia, mean Charlson score, duration of hospitalization before infection onset and laboratory markers at onset of infection, including WBCs and platelets. Both groups had similar rates of septic shock at diagnosis (about one-third of the patients). The rate of bacteraemia was low and similar in both groups (four patients in the trimethoprim/sulfamethoxazole group versus six patients in the vancomycin group).
Thirty day mortality was significantly lower in the trimethoprim/sulfamethoxazole group compared with the vancomycin At least two species in the same sputum specimen. Table 3 . All clinically important variables were included in the model. The multivariate model confirms that vancomycin treatment was associated with a significantly higher risk of 30 day mortality compared with trimethoprim/sulfamethoxazole (HR " 5.28; 95% CI " 1.50-18.60; P50.05), along with other known risk factors, such as age, length of hospitalization and poor functional status.
In order to reduce bias affecting the decision to use a specific antibiotic and as a sensitivity analysis, a propensity-score model for choice between vancomycin and trimethoprim/sulfamethoxazole was used to match patients. The propensity-score model included age, sex, department, presence of diabetes mellitus, ambulatory status, cognitive function, presence of a central line and urinary catheter, mechanical ventilation, respiratory failure and ventilator-associated pneumonia/healthcare-associated pneumonia status. Matching resulted in a mean reduction of 68% in the standardized mean difference, and all covariates had a standardized mean difference of50.2. The matching procedure produced two equal groups of 24 patients (Table 4) The rate of side effects that could be attributed to antibiotic treatment was low in both arms, with only one case of acute renal failure in each arm, two skin manifestations and one case of leucopenia in the trimethoprim/sulfamethoxazole arm versus none in the vancomycin group.
Discussion
The results from this study suggest that the efficacy of trimethoprim/sulfamethoxazole in MRSA pneumonia is superior to that of vancomycin, with a similar safety profile. Patients treated with trimethoprim/sulfamethoxazole showed a significantly lower 30 day mortality compared with vancomycin in both multivariate analysis and sensitivity analysis with propensity score. Trimethoprim/sulfamethoxazole also showed a lower clinical failure rate compared with vancomycin, as well as in the sensitivity analysis with propensity score.
Several reasons exist to search for antibiotics other than vancomycin for MRSA infections. The use of vancomycin has led to the development of S. aureus strains with partial or complete resistance to vancomycin [vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA), respectively]. 12, 13 Vancomycin use has also been associated with the appearance of VRE species.
14 Nosocomial infections with VISA and VRE are difficult to treat and may spread rapidly in the hospital. Finally, vancomycin cannot be administered orally. 15 These failings are all more pronounced when treating MRSA pneumonia, probably due to the poor penetration of vancomycin into pulmonary tissue and lung epithelial lining fluid. 6 This has resulted in high failure rates being observed in the treatment of MRSA pneumonia with vancomycin. A retrospective trial assessing 268 patients with MRSA pneumonia demonstrated a 28% clinical failure rate and 28 day mortality of 22% with vancomycin and the authors called for trials to evaluate the treatment benefit of non-vancomycin alternatives. 16 Other studies quote a 30 day mortality as high as 76%. 17 Few RCTs have compared trimethoprim/sulfamethoxazole with other treatment alternatives in MRSA infections. In a recent RCT, trimethoprim/sulfamethoxazole combined with rifampicin was compared with linezolid for the treatment of MRSA infections, showing no differences in failure/relapse rates or mortality, but low mortality rates for both arms (10%). 9 This study, once again, included few patients with pneumonia in each arm (nine in the trimethoprim/sulfamethoxazole arm versus eight in the linezolid Trimethoprim/sulfamethoxazole for treating MRSA pneumonia JAC arm), so that the study was underpowered to detect statistically significant differences for MRSA pneumonia. In our centre, the susceptibility of nosocomial bloodstream MRSA isolates to trimethoprim/sulfamethoxazole is 490%. MRSA isolates have retained susceptibility to trimethoprim/sulfamethoxazole in many locations worldwide despite several decades of exposure to the antibiotic. Susceptibility rates of490% have been described in contemporary reports for community-associated MRSA and nosocomial MRSA isolates in the USA, Canada, Japan, Europe and Turkey. [18] [19] [20] [21] [22] [23] The main current treatment options for MRSA pneumonia other than vancomycin and trimethoprim/sulfamethoxazole include linezolid (oral), telavancin and ceftaroline (intravenous). Linezolid was superior in terms of clinical success to vancomycin when these agents were compared for the treatment of hospital-acquired MRSA pneumonia (224 patients in each arm), while the 60 day mortality was similar. 10 A recent meta-analysis that included nine RCTs comparing linezolid with vancomycin for hospital-acquired pneumonia concluded that both have similar efficacy and safety profiles. 24 Telavancin was non-inferior to vancomycin in hospitalacquired pneumonia (293 patients with MRSA, overall mortality in the study of 19%). 25 Although ceftaroline is also approved for the treatment of community-acquired bacterial pneumonia, the two randomized, double-blind clinical trials performed for this indication (FOCUS I and II) did not include patients with MRSA. 26 Our trial has several limitations. The retrospective design is the main limitation of our study. Selection bias is another major consideration. While our treatment groups were well matched, there was still a significantly lower albumin level in the vancomycintreated group. We attempted to compensate for this limitation by a sensitivity analysis with a propensity-score model, but this resulted in a lower number of participants in each group. Second, we followed a strict definition of pneumonia for our study, adopted from previous RCTs. If we had chosen a more practical definition of pneumonia, we would have included larger study groups. Third, the rate of side effects was very low in our study. The high mortality rate indicates that the patients were very ill and due to our study's retrospective nature it was difficult to define whether side effects were related to the study drug or to other reasons. Finally, a vancomycin level was determined in only 11/39 patients (28%). Even then, the dosing of vancomycin and trough levels achieved [15 mg/L in only 7/11 (63%) of patients] were lower than currently recommended, 27 potentially resulting in an underestimation of the efficacy of vancomycin and influencing the difference between the two arms.
We conclude that within the limitations of a small, retrospective study, trimethoprim/sulfamethoxazole had an efficacy profile superior to that of vancomycin in the treatment of MRSA pneumonia, with lower rates of overall mortality and the same safety profile. Trimethoprim/sulfamethoxazole may offer an attractive therapeutic option for MRSA pneumonia. However, a large-scale, prospective RCT should be performed in order to strengthen the evidence and promote its use in clinical practice.
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